-62.0%
ALNY vs GSK
+14.9%
-76.9%
-66.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | +5.0% | -4.3% | -1.8% |
| 7D | -30.7% | +4.9% | -35.6% | -32.4% |
| 30D | -26.7% | +9.9% | -36.6% | -30.6% |
| 3M | -26.4% | +0.2% | -26.6% | -26.7% |
| 6M | -45.9% | +2.3% | -48.3% | -46.3% |
| YTD | -59.5% | +7.1% | -66.6% | -60.7% |
| 1Y | -62.0% | +13.1% | -75.1% | -63.6% |
| All | -62.0% | +14.9% | -76.9% | -63.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling